Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Donald McAfee"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
The Journal of Physiology. 592:419-419
Papp et al. (2013) raise a number of salient points in disputing the importance of INa,L in diastolic dysfunction in HFpEF. First, they question the selective effect of enhanced INa,L on passive relaxation when one would expect increased INa,L to aff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bba29157bb6baf941cfc1a0e01c3c40d
https://doi.org/10.1113/jphysiol.2013.268896
https://doi.org/10.1113/jphysiol.2013.268896
Publikováno v:
Journal of General Physiology. 153
KCNQ1 is a pore-forming K+ channel subunit critically important to cardiac repolarization at high heart rates. (2R)-N-[4-(4-methoxyphenyl)-2-thiazolyl]-1-[(4-methylphenyl)sulfonyl]-2 piperidinecarboxamide, or ML277, is an activator of this channel th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb1bccb9f66563e99a92abbd8b8e0be
https://doi.org/10.1085/jgp.202112969
https://doi.org/10.1085/jgp.202112969
Publikováno v:
The Journal of General Physiology
IKs channels are important for repolarization of cardiac action potentials during stress, but the mechanism has not been described microscopically. Thompson et al. show that cAMP facilitates voltage sensor activation in single channels, causing fewer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db6c3c5a20f719a104b8656ff8c4ec60
https://doi.org/10.1085/jgp.201611734
https://doi.org/10.1085/jgp.201611734
The delayed potassium rectifier current, I(Ks,) is assembled from tetramers of KCNQ1 and varying numbers of KCNE1 accessory subunits in addition to calmodulin. This channel complex is important in the response of the cardiac action potential to sympa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab788ebab67e92575878d9feb8eda379
https://europepmc.org/articles/PMC6224683/
https://europepmc.org/articles/PMC6224683/
Publikováno v:
The Journal of Physiology. 592:411-414
Approximately half of all patients with heart failure have an ejection fraction greater than 40–50% and may be diagnosed as having Heart Failure with preserved Ejection Fraction (HFpEF). Diastolic dysfunction is central to the pathophysiology of HF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b606dc70f2ce2f36db2e299ecad81cf
https://doi.org/10.1113/jphysiol.2013.262261
https://doi.org/10.1113/jphysiol.2013.262261
Autor:
Donald McAfee, James D. Johnson, Leonard J. Foster, S. R. Wayne Chen, Edwin D.W. Moore, Parisa Asghari, Nichollas E. Scott, Rich Wambolt, Michael F. Allard, Razvan F. Albu, Jerzy E. Kulpa, Thibault Mayor, Lubos Bohunek, Haoning Cen, Michael J. Bround, Christoph H. Borchers, Jun Han, Marc Pourrier, Roger W. Brownsey, David Fedida
Publikováno v:
The Journal of biological chemistry. 291(45)
Cardiac ryanodine receptor (Ryr2) Ca2+ release channels and cellular metabolism are both disrupted in heart disease. Recently, we demonstrated that total loss of Ryr2 leads to cardiomyocyte contractile dysfunction, arrhythmia, and reduced heart rate.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::887e34396318750f5977c7d4d9e61d5e
https://pubmed.ncbi.nlm.nih.gov/27621312
https://pubmed.ncbi.nlm.nih.gov/27621312
Autor:
Cheryl R. Killingsworth, Raymond E. Ideker, John K. Gibson, Donald McAfee, Jian Huang, Jeffery J Wheeler, Marlowe J. Schneidkraut, Jeff Bechard
Publikováno v:
Journal of Cardiovascular Pharmacology. 57:302-307
Vernakalant is a novel antiarrhythmic agent that has demonstrated clinical efficacy for the treatment of atrial fibrillation. Vernakalant blocks, to various degrees, cardiac sodium and potassium channels with a pattern that suggests atrial selectivit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab48dd383adf6c694f815c4ec0185008
https://doi.org/10.1097/fjc.0b013e3182073c94
https://doi.org/10.1097/fjc.0b013e3182073c94
Publikováno v:
Biophysical Journal. 114:121a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70fc7eed8632cfd19e1245d46536e569
https://doi.org/10.1016/j.bpj.2017.11.694
https://doi.org/10.1016/j.bpj.2017.11.694
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 88(3)
Rotigotine is the first, and to date, the only new chemical entity to be formulated for transdermal delivery. Although first approved for the management of Parkinson’s disease in Europe in 2007 and Restless Leg Syndrome in 2008, the story of rotigo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7da03c91a6df7ce362081924db6e39d1
https://pubmed.ncbi.nlm.nih.gov/25173087
https://pubmed.ncbi.nlm.nih.gov/25173087